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1. Introduction 
Somatoform disorders are characterized by physical symptoms that suggest a medical 
condition but that are not fully explained by a medical condition. Patients presenting with 
somatoform disorders represent a formidable challenge to the health care system. These 
patients tend to overuse health care services, derive little benefit from treatment, and 
experience protracted impairment, often lasting many years (Smith, Monson, & Ray, 1986a). 
Many patients with somatoform symptoms are dissatisfied with the medical services they 
receive and repeatedly change physicians (Lin et al., 1991). Likewise, physicians of these 
treatment-resistant patients often feel frustrated by patients’ frequent complaints and 
dissatisfaction with treatment (Hahn, 2001; Lin et al., 1991). Because standard medical care 
has been relatively unsuccessful in treating somatoform disorders, alternative treatments 
have been developed. Cognitive-behavioral therapy (CBT) has been the most widely studied 
alternative treatment for these disorders.  
Although medicine has long recognized a group of patients with medically unexplained 
physical symptoms, excessive health concerns, and abnormal illness behavior, there has 
been and continues to be disagreement over precise diagnostic labels and criteria. The 
history of the somatoform disorders begins with hysteria and hypochondriasis. The 
Egyptians were the first to describe hysteria about 4,000 years ago. Typical cases involved 
pain in the absence of any injury or pathology in the location of the pain. The Egyptian 
theory held that a wandering uterus moved about the body and produced pain from various 
regions (Veith, 1965). The Greeks gave us the word hysteria, from the Greek hystera, meaning 
womb. Hypochondriasis, also recognized in ancient times, was attributed to disturbances in 
the upper abdominal organs, such as the spleen and the stomach (Ladee, 1966). 
The category of somatoform disorders was not officially recognized until the publication of 
DSM-III. The original DSM-III category of somatoform disorders included somatization 
disorder, hypochondriasis, conversion disorder, psychogenic pain disorder, and a residual 
somatoform disorder category (APA, 1980). The subsequent two editions of DSM included 
the same disorders with variations in their labels and diagnostic criteria (APA, 1987, 1994). 
Dysmorphophobia, later named body dysmorphic disorder, was considered a residual 
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somatoform disorder in DSM-III and categorized as a distinct disorder in DSM-III-R and 
DSM-IV (APA, 1980, 1987, 1994). Table 1 outlines the disorders included in each of the 
editions of DSM. 
The chapter provides a review of the diagnostic criteria for the somatoform disorders, 
according to DSM-IV. Also, summarized is the research on the demographic and clinical 
characteristics of patients who meet criteria for somatoform disorders as well as the 
randomized controlled trials examining the efficacy of cognitive behavioral therapy (CBT) 
for somatoform disorders. Future directions for classification and treatment are also 
discussed.  
DSM-III DSM-III-R DSM-IV Proposed DSM-5 
Somatization disorder Somatization disorder Somatization disorder  
Hypochondriasis Hypochondriasis Hypochondriasis Complex somatic 
symptom dis 
Psychogenic pain 
disorder 
Somatoform pain 
disorder 
Pain disorder Simple somatic 
symptom dis 
 Undifferentiated 
somatoform disorder 
Undifferentiated 
somatoform disorder 
Illness anxiety 
disorder 
Conversion disorder Conversion disorder Conversion disorder Neurological 
functional disorder 
Atypical somatoform 
disorder 
Body dysmorphic 
disorder 
Body dysmorphic 
disorder 
 
 Somatoform disorder 
NOS 
Somatoform disorder 
NOS 
 
   Psychological factors 
affecting medical 
condition 
Table 1. Somatoform Disorders 1980 - Present 
2. Somatization disorder and subthreshold somatization 
2.1 Diagnostic criteria and prevalence  
In DSM-IV somatization disorder is characterized by a lifetime history of at least four 
unexplained pain complaints (e.g., in the back, chest, joints), two unexplained non-pain 
gastrointestinal complaints (e.g., nausea, bloating), one unexplained sexual symptom 
(e.g., sexual dysfunction, irregular menstruation), and one pseudo-neurological symptom 
(e.g., seizures, paralysis, numbness) (APA, 1994). For a symptom to be counted toward the 
diagnosis of somatization disorder its presence must be medically unexplained or its 
degree of severity be substantially in excess of the associated medical pathology. Also, 
each symptom must either prompt the seeking of medical care or interfere with the 
patient’s functioning. In addition, at least some of the somatization symptoms must have 
occurred prior to the patient’s 30th birthday (APA, 1994). The course of somatization 
disorder tends to be characterized by symptoms that wax and wane, remitting only to 
return later and/or be replaced by new unexplained physical symptoms. Thus, 
somatization disorder is a chronic, polysymptomatic disorder whose requisite symptoms 
need not be manifested concurrently. 
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Epidemiological research suggests that somatization disorder is relatively rare. The 
prevalence of somatization disorder in the general population has been estimated to be 0.1% 
to 0.7% (Faravelli et al., 1997; Robins & Reiger, 1991; Weissman, Myers, & Harding, 1978). 
When patients in primary care, specialty medical, and psychiatric settings are assessed, the 
rate of somatization is higher than in the general population, with estimates ranging from 
1.0% to 5.0% (Altamura et al., 1998; Fabrega, Mezzich, Jacob, & Ulrich, 1988; Fink, Steen 
Hansen, & Søndergaard, 2005; Gureje, Simon, et al., 1997; Kirmayer & Robbins, 1991; 
Peveler, Kilkenny, & Kinmoh, 1997). 
Although somatization disorder is classified as a distinct disorder in DSM-IV, it has been 
argued that somatization disorder represents the extreme end of a somatization continuum 
(Escobar, Burnam, Karno, Forsythe, & Golding, 1987; Kroenke, et al., 1997). The number of 
unexplained physical symptoms reported correlates positively with the patient’s degree of 
emotional distress and functional impairment (Katon, et al., 1991). A broadening of the 
somatization construct has been advocated by those wishing to underscore the many 
patients encumbered by unexplained symptoms that are not numerous enough to meet 
criteria for full somatization disorder (Escobar, et al., 1987; Katon et al., 1991; Kroenke et al., 
1997).  
DSM-IV includes a residual diagnostic category for subthreshold somatization cases. 
Undifferentiated somatoform disorder is a diagnosis characterized by one or more medically 
unexplained physical symptom(s) that are distressing and/or disruptive and that have 
lasted for at least six months (APA, 1994). Long considered a category that is too broad 
because it includes patients with only one unexplained symptom as well as those with many 
unexplained symptoms, undifferentiated somatoform disorder never has been well-
validated or widely applied (Kroenke, Sharpe, & Sykes, 2007).  
Two research teams have suggested categories for subthreshold somatization using criteria 
less restrictive and requiring less extensive symptomatology than the standards for DSM-
IV’s full somatization disorder. Escobar and colleagues proposed the label, abridged 
somatization, to be applied to men experiencing four or more unexplained physical 
symptoms or to women experiencing six or more unexplained physical symptoms (Escobar, 
et al., 1987). Kroenke et al. suggested the category of multisomatoform disorder to describe 
men or women currently experiencing at least three unexplained physical symptoms and 
reporting a two-year history of somatization (Kroenke et al., 1997).  
Both of these subthreshold somatization categories appear to be significantly more prevalent 
than is somatization disorder as defined by DSM-IV. Abridged somatization has been 
observed in 4% of community samples (Escobar, et al., 1987) and 16% to 22% of primary care 
samples (Escobar, Waitzkin, Silver, Gara, & Holman, 1998; Gureje, Simon et al., 1997; 
Kirmayer & Robbins, 1991). The occurrence of multisomatoform disorder has been 
estimated at 8% of primary care patients (Jackson & Kroenke, 2008; Kroenke et al., 1997).  
2.2 Demographic and clinical characteristics 
The demographic characteristic most often associated with somatization is gender. In the 
Epidemiological Catchment Area (ECA) study, women were 10 times more likely to meet 
criteria for somatization disorder than were men (Swartz, Landermann, George, Blazer, & 
Escobar, 1991). Higher rates of occurrence in women, though not as extreme, also have been 
www.intechopen.com
 
Standard and Innovative Strategies in Cognitive Behavior Therapy 
 
120 
found in most studies employing subthreshold somatization categories, such as Escobar’s 
abridged somatization or Kroenke’s multisomatoform disorder (Escobar, Rubio-Stipec, 
Canino, & Karno, 1989; Kroenke et al., 1997). A more complex picture of the association 
between gender and somatization was suggested by the WHO’s Cross-National study in 
which female primary care patients were more likely to meet criteria for full somatization 
disorder, but no more likely to meet Escobar’s abridged somatization criteria than were their 
male counterparts (Gureje, Simon, et al., 1997). On the severe end of the continuum, 
somatization disorder is uncommon in men. Gender differences are less obvious in the 
various subthreshold syndromes. 
Ethnicity, race, and education have been associated with somatization disorder and 
subthreshold somatization. Epidemiological research has shown somatization patients more 
likely to be non-white and less educated than non-somatizers (Gureje, Simon, et al., 1997; 
Robins & Reiger, 1991). Findings on ethnicity have been less consistent across studies. In the 
ECA study, Hispanics were no more likely to meet criteria for somatization disorder than 
were non-Hispanics (Robins & Reiger, 1991). The WHO study, conducted in 14 different 
countries, revealed a higher incidence of somatization, as defined by either ICD-10 or 
Escobar’s abridged criteria, in Latin American countries than in the United States (Gureje, 
Simon, et al., 1997).  
Much attention has focused on somatization patients’ illness behavior and the resulting 
impact of that behavior on the health care system. These patients disproportionately use and 
misuse health care services. When standard diagnostic evaluations fail to uncover organic 
pathology, somatization patients tend to seek additional medical procedures, often from 
several different physicians. Patients may even subject themselves to unnecessary 
hospitalizations and surgeries, which introduce the risk of iatrogenic illness (Fink, 1992). 
One study found that somatization disorder patients, on average, incurred nine times the 
US per capita health care cost (Smith et al., 1986a). Abridged somatization and 
multisomatoform disorder also have been associated with significant health care utilization 
(Barsky, Orav, & Bates, 2005; Escobar, Golding, Hough, Karno, Burnam, & Wells, 1987; 
Kroenke et al., 1997). 
The abnormal illness behavior of somatizing patients extends beyond medical offices and 
hospitals to patients’ workplaces and households. Somatizers withdraw from both 
productive and pleasurable activities because of discomfort, fatigue, and/or fears of 
exacerbating their symptoms. In a study assessing the efficacy of cognitive behavior therapy 
for somatization disorder, we found 19% of patients meeting DSM-IV criteria for 
somatization disorder to be receiving disability payments from either their employers or the 
government (Allen, Woolfolk, Escobar, Gara, & Hamer, 2006). Estimates of unemployment 
among somatization disorder patients range from 36% to 83% (Allen et al., 2006; Smith et al., 
1986a; Yutzy et al., 1995). Whether working outside their homes or not, these patients report 
substantial functional impairment. Some investigators have found that somatization 
disorder patients report being bedridden for 2 to 7 days per month (Katon et al., 1991; Smith 
et al., 1986a). Likewise, high levels of functional impairment have been associated with 
subthreshold somatization (Allen, Gara, Escobar, Waitzkin, Cohen-Silver, 2001; Escobar, 
Golding, et al., 1987; Gureje, Simon, et al., 1997; Jackson & Kroenke, 2008; Kroenke et al., 
1997). 
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In addition to their physical complaints, many somatization patients complain of psychiatric 
distress. As many as 80% of patients meeting criteria for somatization disorder or 
subthreshold somatization meet DSM criteria for another lifetime Axis I disorder, usually an 
anxiety or mood disorder (Smith et al., 1986a; Swartz, Blazer, George, & Landerman, 1986). 
When investigators consider only current psychiatric diagnoses, rates of Axis I psychiatric 
co-morbidity associated with somatization are closer to 50% (Allen, Gara, Escobar, Waitzkin, 
Cohen-Silver, 2001; Simon & Von Korff, 1991). Rates of Axis II psychiatric co-morbidity also 
are high (Garcia-Campayo, Alda, Sobradiel, Olivan, & Pascual, 2007; Rost, Akins, Brown, & 
Smith, 1992). Also, overall severity of psychological distress, defined as the number of 
psychological symptoms reported, correlates positively with the number of functional 
somatic symptoms reported (Katon et al., 1991; Simon & Von Korff, 1991).  
2.3 Cognitive behavioral treatment  
A number of studies have been conducted examining the efficacy of cognitive behavioral 
therapy (CBT) for somatization disorder or for subthreshold somatization. Two studies 
enrolled patients with at least one somatization symptom. Two other studies enrolled 
patients with multiple medically unexplained symptoms. Only study one enrolled patients 
meeting DSM-IV criteria for somatization disorder, the most severely disturbed 
somatizating patients. Various different approaches to integrating CBT into primary care 
have also been investigated.  
The earliest randomized controlled trials on CBT for somatization included patients 
presenting with relatively mild levels of somatization, patients presenting with at least one 
psychosomatic symptom. The treatment protocols included identifying and restructuring 
dysfunctional cognitions, behavioral activation or reengaging patients in avoided activities, 
problem-solving, and relaxation training (Lidbeck, 1997; Speckens et al., 1995). In the first 
study patients treated with 6 to 16 sessions of individually-administered CBT showed 
significantly greater improvement in their psychosomatic complaints than did patients 
treated with standard medical care (Speckens et al., 1995). The other study found an 8-
session group CBT superior to a waiting-list control condition in reducing physical 
symptoms and hypochondriacal beliefs (Lidbeck, 1997). In both studies improvements were 
observed after treatment as well as six months later (Lidbeck, 1997; Speckens et al., 1995). 
Both of these studies were conducted in primary care offices, the setting where somatization 
is most likely to be seen.  
Two more recently published randomized controlled trials examined the efficacy of CBT for 
somatization with patients presenting with more severe somatization than the earlier trials. 
One study required participants meet Escobar’s criteria of abridged somatization. That is, 
men were required to experience at least four somatization symptoms and women were 
required to experience at least six somatization symptoms (Escobar et al., 2007). The other 
trial enrolled participants who complained of five or more unexplained physical symptoms 
(Sumathipala, Hewege, Hanwella, & Mann, 2000). In both studies patients were identified 
and treated with CBT in primary care. Treatment protocols were similar to that of Lidbeck 
(1997) and Speckens et al., (1995) with the addition of involving the patient’s spouse or other 
family member in treatment (Escobar et al., 2007; Sumathipala et al., 2000). Findings from 
both trials show individual CBT coincided with greater reductions in somatic complaints 
than did standard medical care (Escobar et al., 2007; Sumathipala et al., 2000). CBT was 
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associated with a reduction in the number of physician visits in one study (Sumathipala et 
al., 2000).  
We are the only group of researchers who have published a randomized controlled trial on 
the efficacy of CBT for full somatization disorder (Allen, Woolfolk, Escobar, Gara, & Hamer, 
2006). In the study 84 patients meeting DSM-IV criteria for somatization disorder were 
randomly assigned to one of two conditions: (1) standard medical care or (2) a 10-session 
manualized individually-administered CBT in combination with standard medical care. The 
treatment protocol included relaxation training, activity regulation, facilitation of emotional 
awareness, cognitive restructuring, and interpersonal communication. Although the 
elicitation and exploration of affect is an approach rarely used in CBT, we have found this 
component to be a powerful clinical tool with patients who cannot or do not willingly access 
and experience emotion. We have described our treatment in detail elsewhere (Woolfolk & 
Allen, 2007). Participants’ symptomatology and functioning were assessed with clinician-
administered instruments, self-report questionnaires, and medical records before 
randomization as well as 3 months, 9 months, and 15 months after randomization. Just after 
the completion of treatment as well as one year later, i.e., at the 15-month follow-up 
assessment, patients who received CBT experienced a greater reduction in somatization and 
functional impairment. Substantially more participants who received CBT than the control 
treatment were rated as either “very much improved” or “much improved” by a clinician 
who was blind to participants’ treatment condition (40% vs. 5%, respectively). Also, for the 
68% of the sample for whom complete medical records were reviewed, CBT was associated 
with a reduction in health care costs and physician visits (Allen et al., 2006). Thus, the study 
suggests CBT can result in long-term improvements in the symptomatology, functioning, 
and health care utilization of the most severely disturbed somatizing patients.  
2.4 Integrating CBT into primary care 
Because somatization is so prevalent in primary care practices (Escobar, Waitzkin et al., 
1998; Gureje, Simon et al., 1997; Kirmayer & Robbins, 1991), other approaches to the 
treatment of somatization have been focused on primary care physicians’ behavior. Smith 
and colleagues sent a psychiatric consultation letter to patients’ primary care physicians, 
describing somatization disorder and providing recommendations to guide primary care 
(Smith, Monson, & Ray, 1986b). The recommendations to physicians were 
straightforward: (a) to schedule somatizers’ appointments every 4 to 6 weeks instead of 
"as needed", (b) to conduct a physical examination in the organ system or body part 
relevant to the presenting complaint, (c) to avoid diagnostic procedures and surgeries 
unless clearly indicated by underlying somatic pathology, and (d) to avoid making 
disparaging statements, such as “your symptoms are all in your head.” Patients whose 
primary physicians had received the consultation letter experienced better health 
outcomes, such as physical functioning and cost of medical care, than those whose 
physicians had not received the letter. The results were replicated in three additional 
studies, one study using patients meeting criteria for full somatization disorder (Rost, 
Kashner, & Smith, 1994) and two studies using patients with subthreshold somatization 
(Dickinson, et al., 2003; Smith, Rost, & Kashner, 1995). 
Given the success of the above-described consultation letter and the success of CBT, some 
investigators have attempted to train primary care physicians to better detect somatization 
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and to incorporate cognitive and behavioral techniques into their treatment of these 
patients. Five groups of investigators have reported controlled clinical trials on the effects of 
such physician training (Arnold et al., 2009; Larish, Schweickhardt, Wirsching, & Fritzsche, 
2004; Morriss et al., 2007; Rief, Martin, Rauh, Zech, & Bender, 2006; Rosendal et al., 2007). 
The two studies providing the most extensive physician training (20-25 hours) resulted in no 
association between physician training and patients’ symptomatology, functioning, or quality 
of life (Arnold et al., 2009; Rosendal et al., 2007). Three other studies found less intensive 
physician training programs, 12 hours (Larish et al., 2004) or 1 day (Rief et al., 2006) or six 
hours (Morriss et al., 2007) to coincide with no clear improvement in somatization 
symptomatology; however, Rief and colleagues did find their training to coincide with fewer 
health care visits for the 6 months subsequent to training (Rief et al., 2006).  
One other study examined the effect of training primary care clinicians to identify and treat 
somatization using a biopsychosocial model (Smith et al., 2006). This study involved the 
most intensive such training programs studied, one entailing 84 hours over 10 weeks. Nurse 
practitioners were trained to provide a year-long 12-session multidimensional intervention 
in primary care that incorporated biopsychosocial conceptualizations of, behavioral 
recommendations for, and medication management of somatization. Patients who received 
treatment from these trained nurses reported modest improvements on self-report scales of 
mental health such as mood and energy and physical functioning. A post hoc analysis was 
interpreted by the study’s investigators as suggesting improvements were attributable to 
more frequent and appropriate use of antidepressant medication among patients of nurses 
who received the training (Smith et al., 2006).  
A slightly different model for integrating CBT into primary care is a collaborative care 
model of treatment, in which mental health professionals work together with medical 
practitioners in the primary care setting (Katon et al., 1995; von Korff, Gruman, Schaefer, 
Curry & Wagner, 1997). The one study investigating the efficacy of such a model for the 
treatment of somatization had psychiatrists provide primary care physicians and their staff 
with training on the diagnosis and treatment of somatization and comorbid 
psychopathology (van der Feltz-Cornelis, van Oppen, Ader, & van Dyck, 2006). Also, the 
psychiatrist provided case-specific consultations to primary physicians regarding referrals 
for CBT and/or psychiatric treatment (van der Feltz-Cornelis et al., 2006). A control 
comparison treatment included the same training for primary care physicians and their staff 
by the psychiatrist without the case-specific consultation. Six months after randomization, 
participants whose primary care physician received psychiatric consultation reported a 
greater reduction in somatic symptoms and in health care visits (van der Feltz-Cornelis et 
al., 2006).  
In all, the literature on the treatment of somatization supports the use of 6-16 sessions of 
CBT administered by a mental health professional. A recent meta-analysis indicated CBT 
is modestly effective in reducing somatization symptomatology and minimally effective 
improving physical functioning (Kleinstäuber, Witthöft, & Hiller, 2011). To date there is 
no evidence that CBT reduces health care services when the cost of CBT itself is 
considered. Researchers have just begun to develop and examine the effectiveness of true 
collaboration between cognitive behavioral therapists and primary care clinicians and 
integration of their services.  
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3. Hypochondriasis 
3.1 Diagnostic criteria and prevalence  
According to DSM-IV, hypochondriasis is defined as a “preoccupation with fears of having, 
or the idea that one has, a serious disease based on the person’s misinterpretation of bodily 
symptoms” (APA, 1994, p. 462). This preoccupation must last for at least six months, persist 
despite medical evaluation and physician reassurance, and cause significant distress or 
impairment in one’s functioning (APA, 1994). Thus, unlike in somatization where the 
distress and dysfunction experienced is due to the physical symptoms themselves, in 
hypochondriasis the distress and dysfunction is due to the patient’s interpretation of the 
meaning of his or her symptoms. The course of hypochondriasis is often chronic: As many 
as 50% of patients meeting DSM criteria for hypochondriasis have excessive health concerns 
for many years (Barsky, Fama, Bailey & Ahern, 1998; Barsky, Wyshak, Klerman, & Latham, 
1990). 
There are only a few epidemiological studies that have examined the prevalence of 
hypochondriasis. Studies that have utilized a clinical interview to assess prevalence have 
suggested that hypochondriasis occurs rarely in the general population. Such estimates 
range from 0.02 to 1.6% (Faravelli et al., 1997; Looper & Kirmayer, 2001; Martin & Jacobi, 
2006). In primary care, estimates range from 0.8% to 6.3% (Barsky et al., 1990; Escobar, Gara, 
et al. 1998; Gureje, Ustun, & Simon, 1997). 
3.2 Demographic and clinical characteristics 
Unlike somatization disorder, hypochondriasis does not appear to be related to gender 
(Barsky et al, 1990; Gureje, et al., 1997; Looper & Kirmayer, 2001). Men are as likely to meet 
DSM criteria for hypochondriasis as are women. Findings have been inconsistent on 
whether hypochondriasis is related to education, socio-economic status, and ethnicity 
(Barsky et al., 1990; Gureje, et al., 1997). 
Like patients with somatization disorder and milder versions of somatization disorder, 
those with hypochondriasis exhibit abnormal illness behavior. They over-utilize health care 
(Gureje, Ustun, et al., 1997; Looper & Kirmayer, 2001), subjecting themselves to multiple 
physician visits and multiple diagnostic procedures. They report great dissatisfaction with 
their medical care (Barksy, 1996; Noyes et al., 1993). In addition, patients diagnosed with 
hypochondriasis report substantial physical impairment and functional limitations related 
to employment (Escobar et al., 1998; Gureje, Ustun, et al., 1997; Looper & Kirmayer, 2001; 
Noyes et al., 1993). Also, hypochondriasis frequently co-occurs with other Axis I disorders, 
such as mood, anxiety, or other somatoform disorders (Gureje, Ustun, et al., 1997; Noyes et 
al., 1994) and various Axis II disorders (Sakai, Nestoriuc, Nolido, & Barsky, 2010). 
3.3 Cognitive behavioral treatment  
Psychosocial treatments for hypochondriasis have been examined in six randomized 
controlled trials. The interventions in all six studies were brief (i.e., 6 to 16 sessions), 
theoretically grounded in social learning theory, and administered on an individual basis. 
Three groups of investigators examined the efficacy of CBT (Barsky & Ahern, 2004; 
Greeven et al., 2007; Warwick, Clark, Cobb, & Salkovskis, 1996). Two other trials 
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examined the efficacy of treatments, labeled cognitive therapy (CT) (Clark et al., 1998; 
Visser & Bouman, 2001). Behavioral stress management, exposure in vivo plus response 
prevention, and explanatory therapy have also been studied, each in one randomized 
controlled trial. Below we provide an elaboration of the specific interventions and a 
review of the studies’ findings. 
All treatments labeled CBT or CT involved identifying and challenging patients’ 
misinterpretations of physical symptoms as well as constructing more realistic 
interpretations of them (Barsky & Ahern, 2004; Clark et al., 1998; Greeven et al., 2007; Visser 
& Bouman, 2001; Warwick, Clark, Cobb, & Salkovskis, 1996). Visser and Bouman’s (2001) 
CT consisted of a “pure CT” that focused on only cognitive elements of treatment. Clark et 
al.’s CT (1998), on the other hand appears to be procedurally similar to the point of being 
indistinguishable from many of those labeled CBT for hypochondriasis (Greeven et al., 2007; 
Warwick, Clark, Cobb, & Salkovskis, 1996). Specifically, most CBT and Clark et al.’s CT 
combined cognitive restructuring with exposure to interoceptive and/or external stimuli 
along with response prevention after exposure (Clark et al., 1998; Greeven et al., 2007; 
Warwick et al., 1996). Barsky and Ahern’s CBT did not include exposure plus response 
prevention. Instead, they attempted to reduce patients’ tendency to amplify physical 
symptoms and to alter patients’ illness behaviors, in addition to restructuring cognitions 
(Barsky & Ahern, 2004). Another difference among the treatments was their durations. 
Barsky and Ahern’s (2004) treatment entailed six 90-min sessions. Visser and Bouman’s 
(2001) intervention consisted of 12 weekly sessions, each presumably lasting 1 hour, though 
session duration was not indicated. The duration of Greeven et al.’s (2007) CBT which was 
“based on the treatment protocol used by Visser and Bouman,” (p. 93) ranged from 6 to 16 
sessions. Both Clark et al.’s (1998) and Warwick et al.’s (1996) treatments involved 16 1-hour 
sessions. 
All CT and CBT interventions were associated with significantly greater reductions in 
hypochondriacal symptoms than was the comparable waiting list or standard medical care 
control condition (Barsky & Ahern, 2004; Clark et al., 1998; Greeven et al., 2007; Visser & 
Bouman, 2001; Warwick, et al., 1996). Barsky and Ahern’s study was the only one that 
examined long-term differences between the control group and the treated group: Ten 
months after treatment completion, patients enrolled in CBT reported a greater decline in 
hypochondriacal cognitions than did controls. Also, Barsky and Ahren’s CBT-treated 
participants reported a significantly greater increase in daily activities than did controls, 
even 10 months after treatment (Barsky & Ahern, 2004). 
In addition to their pure CT condition, Visser and Bouman (2001) also assessed the efficacy 
of a largely behavioral intervention, exposure plus response prevention. Patients receiving 
this treatment constructed hierarchies of their own hypochondriacal fears and avoidance 
behavior patterns, such as checking, reassurance seeking, avoidance of interoceptive and/or 
external stimuli. Afterwards, they were given assignments of in vivo exposure and response 
prevention. Patients treated with exposure reported significantly greater reductions in their 
hypochondriacal symptoms than did wait-list control participants. Although Visser and 
Bouman also compared exposure plus response prevention to their CT intervention 
described above, the study was not sufficiently powerful to distinguish between the two 
treatments.  
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Clark et al. (1998) created a psychosocial alternative to CT, behavioral stress management 
(BSM) that did not directly address hypochondriacal concerns. It was intended to address 
anxiety related to hypochondriasis by training patients in relaxation, problem-solving, 
assertiveness training, and time management. Clark et al. (1998) found behavioral stress 
management significantly more effective in alleviating hypochondriacal concerns than 
was a waiting list. Clark et al. also compared this treatment to their CT described earlier. 
At post-treatment CT-treated participants experienced greater reductions in their 
hypochondrical cognitions than did BSM-treated participants. Nevertheless, 12 months 
after the post-treatment assessment, these differences were not observed (Clark et al., 
1998).  
Finally, Fava et al. examined the efficacy of explanatory therapy (Kellner, 1983) for 
hypochondriasis, in hopes of identifying a beneficial treatment that is less complex and 
easier to administer than CBT (Fava, Grandi, Rafanelli, Fabbri, & Cazzaro, 2000). 
Explanatory therapy is a physician-administered individual therapy consisting of patient 
education, reassurance, and training in selective attention (i.e., reducing somatic attention). 
Like the cognitive and behavioral treatments described above, explanatory therapy resulted 
in greater reductions in worry about illness than did the waiting list (Fava et al., 2000). 
Although explanatory therapy was also associated with greater reductions in physician 
visits than was the control group, the mean reduction in visits was minimal (3 visits) 
considering the treatment group received 8 additional visits as part of their explanatory 
therapy (Fava et al., 2000). 
The one study comparing a psychosocial intervention with a pharmacological intervention 
demonstrated that CBT was more effective than a placebo pill, but no more effective than 
paroxetine, in reducing hypochondriacal beliefs (Greeven et al., 2007). Despite the statistical 
significance of these findings, the clinical significance of changes observed in this study 
suggests that patients experienced only modest improvement. Instead of using Jacobson’s 
recommendation of a change of 1.96 standard deviations from the pretreatment mean as an 
index of clinically significant change, the investigators judged as clinically significant a 
change of 1.0 standard deviation. Using this more lenient criterion, only 45% of CBT 
recipients and 30% of paroxetine recipients versus 14% of waiting list controls responded to 
treatment at clinically significant levels (Greeven et al. 2007). 
3.4 Integrating CBT into primary care 
Given the prevalence of hypochondriasis in medical practices (Barsky et al., 1990; Escobar, 
Gara, et al., 1998; Gureje, Ustun, et al., 1997), it would seem important to develop treatments 
to be administered in medical settings. Only one of the randomized controlled trials 
described above was conducted in primary care (Barsky & Ahern, 2004). All other trials 
were conducted in mental health or psychosomatic medicine clinics, and thus leave open to 
question the generalizability of findings to hypochondriacal primary care patients. Will 
primary care patients with concerns about their physical health be open to a treatment 
designed to challenge the validity of those concerns? A significant proportion (29%) of the 
patients recruited for Barsky and Ahern’s study declined to participate (Barsky & Ahern, 
2004). Future research could examine the efficacy of CBT that is integrated and coordinated 
with primary care.  
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4. Conversion disorder 
4.1 Diagnostic criteria and prevalence  
Conversion symptoms, also described as pseudo-neurological symptoms, are abnormalities 
or deficits in voluntary motor or sensory function that are medically unexplained. Some of 
the most common pseudo-neurological symptoms are pseudo-seizures, pseudo-paralysis 
and psychogenic movement disorders. According to DSM-IV, conversion disorder is 
characterized by the presence of one or more pseudo-neurological symptoms that are 
distressing and/or disruptive and are associated with psychological stressor(s) or conflict(s). 
Also, the symptoms can not be intentionally produced or feigned (APA, 1994). The 
diagnosis of conversion disorder requires a thorough psychiatric evaluation as well as a 
physical examination in order to rule out organic neurological illness. Patients presenting 
with conversion symptoms typically have normal reflexes and normal muscle tone.  
The course of conversion disorder appears to be different from that of somatization 
disorder, which tends to be chronic (Kent, Tomasson, & Coryell, 1995). The onset and course 
of conversion disorder often take the form of an acute episode. Symptoms may remit within 
a few weeks of an initial episode and they may recur in the future. Some research indicates 
that a brief duration of symptoms prior to treatment is associated a better prognosis 
(Crimlisk et al., 1998; Hafeiz, 1980; Ron, 2001).  
Estimates of the prevalence of conversion disorder have varied widely, ranging from 0.01 to 
0.3% in the community (Faravelli et al., 1997; Stefansson, Messina, & Meyerowitz, 1979). As 
is the case with the other somatoform disorders, conversion disorder is much more common 
in medical and psychiatric practices than in community samples. As many as 25% of 
neurology clinic patients may present for treatment of a medically unexplained neurological 
symptom (Creed, Firth, Timol, Metcalf & Pollock, 1990; Perkin, 1989). 
4.2 Demographic and clinical characteristics 
The demographic characteristics of conversion disorder have not been investigated 
extensively. Nevertheless, there is some evidence that conversion disorder is more common 
among women (Deveci et al., 2007; Faravelli et al., 1997), non-whites (Stefansson, et al., 
1979), and individuals from lower socioeconomic classes (Folks, Ford, & Regan, 1984; 
Stefansson, et al., 1979). Co-morbid psychiatric distress in patients with pseudo-neurological 
symptoms is high; it has been estimated that 30% to 90% of patients seeking treatment for 
pseudo-neurological symptoms also meet criteria for at least one other psychiatric disorder, 
typically somatoform disorders, affective disorders, anxiety disorders, or personality 
disorders (Binzer, Andersen, & Kullgren, 1997; Crimlisk et al., 1998; Mokleby, Akyuz, 
Kundakel, Kizitlan & Dogan, 2002; Sar et al., 2004). A co-morbid personality disorder 
diagnosis has been found to indicate poor prognosis of conversion disorder (Mace & 
Trimble, 1996). 
Like somatization disorder, conversion disorder is costly to the health care system, 
especially when symptoms are chronic (Mace & Trimble, 1996). Patients with long-standing 
conversion symptoms are likely to submit themselves to unnecessary diagnostic and 
medical procedures. Martin and colleagues reported an average of $100,000 being spent per 
year per conversion disorder patient (Martin, Bell, Hermann, & Mennemeyer, 2003).  
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4.3 Cognitive behavioral treatment  
We are aware of only one published randomized controlled trial investigating the efficacy of 
CBT for conversion disorder. In the study patients diagnosed by a neurologist as having 
psychogenic nonepileptic seizures were randomly assigned to receive standard 
neuropsychiatry care alone or standard neuropsychiatry care plus individual CBT 
(Goldstein et al., 2010). The 12-session CBT was designed to help patients interrupt 
behavioral, physiological, and emotional responses that occurred at the onset of seizures. 
Specifically, patients were encouraged to engage in avoided activities, utilize relaxation 
methods, and restructure their dysfunctional cognitions (Goldstein et al., 2010). At the 
conclusion of treatment, patients who received CBT reported a greater reduction in 
psychogenic seizures than did the control group. At the 6-month follow up assessment, the 
difference between treatment and control groups was only marginally significant. Health 
care utilization and social and work functioning did not change differentially between the 
treatment groups (Goldstein et al., 2010). 
5. Pain disorder 
5.1 Diagnostic criteria and prevalence  
Pain disorder is characterized by clinically significant pain that is judged to be affected by 
psychological factors (APA, 1994). Very little research has been conducted that addresses 
pain disorder as defined by DSM-IV (or its counterparts, psychogenic pain disorder and 
somatoform pain disorder in DSM-III and DSM-III-R, respectively) as a discrete diagnostic 
category. Instead, researchers have tended to formulate research based on the anatomical 
site and the chronicity of the pain. Thus, there is a voluminous literature on distinct pain 
conditions, e.g., back pain, chest pain, pelvic pain, headaches. In very few of these studies 
have investigators attempted to distinguish between pain that was apparently affected by 
psychological factors and pain that was apparently not, presumably because such a 
distinction is too difficult to make and perhaps unreliable.  
The few investigators who have examined the epidemiology of somatoform pain disorder, 
instead of specific pain syndromes, have not assessed whether psychological factors were 
involved in the onset, severity, exacerbation, or maintenance of the pain, as required by 
DSM-IV. Instead, the diagnosis was made for medically unexplained pain that lasted six 
months and impaired functioning. In these studies, somatoform pain disorder had a one-
year prevalence of 0.6% to 8.1% (Faravelli et al., 1997; Frohlich, Jacobi, & Wittchen, 2005) and 
a lifetime prevalence of 12.3% (Grabe et al., 2003).  
Given the difficulty of determining whether psychological factors are associated pain 
symptoms and the similarity of the presentation of pain disorder with that of somatization 
disorder and subthreshold somatization, many experts have suggested the elimination of 
the pain disorder category from future versions of DSM (Birket-Smith & Mortenson, 2002; 
Kroenke, et al., 2007; Sullivan, 2000). In fact, the most recent proposal for DSM-5 has 
eliminated this diagnostic label (APA, 2010).  
5.2 Demographic and clinical characteristics 
The limited body of research on pain disorder suggests that it is associated with functional 
impairment, overuse of medical services, and psychopathology (Frohlich et al., 2005). 
www.intechopen.com
 
Cognitive Behavioral Therapy for Somatoform Disorders 
 
129 
5.3 Cognitive behavioral treatment  
We are not aware of any published randomized controlled trial investigating the efficacy of 
CBT for DSM-IV pain disorder or for the DSM-III or DSM-III-R counterparts to it. Reviews 
on CBT for specific pain disorders, such as non-cardiac chest pain, chronic back pain, 
headaches, can be found elsewhere and are consistent with the findings for other 
somatoform disorders showing CBT to be associated with modest benefits in 
symptomatology (Kisely, Campbell, Skerritt, & Yelland, 2010; Kröner-Herwig, 2009). 
6. Body dysmorphic disorder 
6.1 Diagnostic criteria and prevalence  
DSM-IV body dysmorphic disorder (BDD) is characterized by a preoccupation with an 
imagined defect in appearance. If a slight physical irregularity is present, the person’s 
concern must be excessive to be meet criteria for BDD. Also required for a diagnosis of BDD 
is significant distress or impairment caused by this preoccupation (APA, 1994). Typically, 
patients are concerned about their skin or complexion, the size of the nose or head, or the 
attractiveness of the hair; however, the preoccupation may concern any body part. 
BDD tends to be chronic. In one study Phillips at al. found only a 0.09 probability of full 
remission and 0.21 probably of partial remission over the course of a year (Phillips, Pagano, 
Menard, & Stout, 2006). 
The prevalence of BDD is uncertain. Research conducted in community settings has 
produced varying estimates: a prevalence of 0.7% in a community setting in Italy 
(Faravelli et al., 1997), 1.7 % in a national survey of German adolescents and adults (Reif, 
Buhlmann, Wilhelm, Borkenhagen, & Brähler, 2006), and 2.4% in a telephone survey of 
U.S. adults (Koran, Abujaoude, Large, & Serpe, 2008). The prevalence of BDD in medical 
practices has been found to be substantially higher than that found in the general 
population: 4% of general medicine patients (Phillips, 1996), 3% to 16% of cosmetic 
surgery patients (Sarwer & Crerand, 2008), and 8% to 15% of dermatology patients 
(Sarwer & Crerand, 2008). 
6.2 Demographic and clinical characteristics 
Relatively little research has been conducted on sex and cultural differences in BDD. Two 
groups of investigators have found that women and men were equally likely to meet criteria 
for BDD (Koran, Abujaoude, Large & Serpe, 2008; Phillips & Diaz, 1997). We are aware of no 
systematic investigation of race and culture in BDD, though the condition has been 
described in various cultures around the world (Phillips, 1996). 
Patients meeting criteria for BDD have been shown to have substantial functional 
impairment (Phillips, 2000). Negative thoughts about one’s appearance interfere with 
concentration at work and the social lives of patients. In addition, individuals with BDD are 
so afraid of exposing their flaw to others that they go to great lengths to hide it. They may 
spend substantial amounts of time camouflaging their perceived defect or avoiding 
activities in which they will be conspicuous (Phillips, McElroy, Keck, Pope, & Hudson, 
1993). Avoidance of social activities and work is common (Phillips et al., 1993).  
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Health care use associated with BDD tends to be directed toward seeking various 
appearance enhancing medical treatments, especially cosmetic surgery and dermatological 
procedures. For patients with BDD these treatments typically fail to alleviate distress 
(Crerand, et al., 2005; Phillips, Grant, Siniscalchi, & Albertini, 2001). Investigators have 
found that 48% to 76% of patients with BDD sought cosmetic surgery, dermatological 
treatment, or dental procedures (Crerand, et al., 2005; Phillips, et al., 2001; Veale, Boocock, et 
al., 1996) and 26% received multiple procedures (Veale, Boocock, et al., 1996).  
Patients meeting criteria for BDD experience an enormous amount of emotional distress and 
psychiatric co-morbidity (Phillips, Menard, Fay, & Weisberg, 2005; Veale, Boocock, et al., 
1996). Depression and suicidal thoughts are frequent (Gunstad & Phillips, 2003; Phillips & 
Menard, 2006). Also common is social phobia and obsessive compulsive disorder (Gunstad 
& Phillips, 2003). Often, compulsions are related to the perceived physical defect, such as 
checking mirrors or brushing one’s hair. Many of these patients also admit to substance, 
particularly alcohol, use and dependence disorders (Grant, Menard, Pagano, Fay, & Phillips, 
2005; Gunstad & Phillips, 2003). Co-morbid personality disorders are likely to be present 
(Phillips & McElroy, 2000).  
Many patients preoccupied with an imagined defect in their physical appearance have such 
inaccurate perceptions of their appearance that they meet DSM-IV criteria for delusional 
disorder, somatic type. About 50% of clinical samples meeting criteria for BDD also meet 
criteria for delusional disorder, somatic type (Phillips, McElroy, & Keck, 1994); however, 
instead of considering this somatic type of delusional disorder a co-morbid condition with 
BDD, a growing body of research suggests psychotic variants of BDD are simply more 
severe forms of non-psychotic BDD and are, therefore, best conceived as on the same 
continuum. It seems that non-psychotic and psychotic BDD share the same demographic 
characteristics, clinical characteristics, and response to treatment (Phillips, 2004). Further 
evidence suggests that the cognitions of BDD patients involving such matters as the degree 
of conviction with which they hold their beliefs are more indicative of a dimensional rather 
than a categorical structure (Phillips, 2004). Thus, the research data suggest a dimensional 
model of BDD with varying levels of insight indicating severity of the condition.  
6.3 Cognitive behavioral treatment 
Only two randomized controlled trials have been published on the efficacy of CBT for BDD 
(Rosen, Reiter, & Orosan, 1995; Veale, Gournay, et al., 1996). Both interventions involved the 
restructuring dysfunctional beliefs about one’s body and exposure to avoided situations 
plus response prevention, for example, preventing checking behavior and reassurance 
seeking. Whereas Rosen et al.’s treatment was administered in eight 2-hour group sessions, 
Veale et al. administered treatment in 12 weekly individual sessions. Both groups of 
investigators compared the effects of CBT with those of a waiting list control condition. 
Both studies provided strong evidence for the short-term efficacy of CBT for BDD. Rosen 
et al. found that 81.5% of treated participants but only 7.4% of control participants 
experienced clinically significant improvement, in that their scores on the Body 
Dysmorphic Disorder Examination (BDDE) dropped more than two standard deviations 
and they no longer met criteria for BDD. The effect size on the BDDE was substantial  
(d = 2.81) (Rosen et al., 1995). Follow-up assessment, occurring 4.5 months after post-
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treatment, was conducted with only CBT participants, 74% of whom continued to have 
achieved clinically meaningful gains (Rosen et al., 1995). Veale et al. reported that at post-
treatment 77.8% of the treatment group either had absent or sub-clinical BDD 
symptomatology whereas all waiting list participants still met criteria for BDD. 
Furthermore, Veale’s effect size on the BDDE and on a BDD-modified Yale Brown 
Obsessive Compulsive Scale were also noteworthy (d = 2.65 and 1.81, respectively) (Veale, 
Gournay, et al., 1996). Follow-up was not investigated in this study. 
In all, CBT for BDD must be considered an evidence based treatment. Although the potency 
of the treatments described in these two well-designed controlled trials is noteworthy, a 
number of questions remain about the efficacy of CBT for BDD. No additional randomized 
controlled trials have been published. CBT has not been compared with alternative 
treatments nor with an attention control. It is unclear whether treatment gains reported 
above could be attributable to nonspecific aspects of therapy. Also, long-term follow-up has 
not been adequately studied. Other important outcomes, such as physical and social 
functioning and health care use, have not been assessed. Finally, the generalizability of these 
findings is unclear. Between the two studies only 36 patients have been treated. Rosen et 
al.’s sample consisted of women, 83% of whom had body weight and shape concerns. Veale 
et al.’s sample specifically excluded potential participants with body weight and shape 
concerns.  
6.4 Integrating CBT into primary care 
Given that patients with BDD are likely to seek treatment from medical practitioners, 
treatment should be administered in primary care. Also, primary care physicians are likely 
to require training in identifying BDD. No published study has assessed an attempt to 
integrate CBT into primary care. 
7. Future research 
7.1 Future research on the classification of somatoform disorders 
In the midst of much debate over nosology of the somatoform disorders (Hyler & Spitzer, 
1978; Mayou, Kirmayer, Simon, Kroenke, & Sharpe, 2005), a number of changes have been 
proposed for DSM-5 by the DSM-5 Somatic Symptom Disorders Work Group (APA, 2010). 
As a general framework for these disorders, there is a shift from emphasizing the functional-
status of somatic symptoms (i.e., that symptoms be medically unexplained) to the 
dysfunctional thoughts, feelings and behaviors related to somatic symptoms. The mind-
body dualism implied by the construct of medically unexplained symptoms as well as the 
unreliability of assessments of a symptom’s true cause (e.g., organic vs. functional) have 
long been identified as shortcomings (Jablensky, 1999; Mayou et al., 2005). Also, numerous 
clinician-researchers have expressed concern using pejorative labels (Kirmayer, 1988). In line 
with these concerns, the terms somatoform, somatization, and hypochondriasis have been 
eliminated from the most recent proposal for DSM-5 (APA, 2010). The overall category will 
be renamed, somatic symptom disorders. Detailed below are the most recent proposals for 
changes to the specific diagnostic categories within somatic symptom disorders group, that 
is, the creation of diagnostic categories and removal of others. 
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7.1.1 Complex somatic symptom disorder 
A new category, complex somatic symptom disorder, has been proposed to subsume 
somatization disorder, undifferentiated somatoform disorder, somatoform pain disorder, 
and most cases of hypochondriasis. The rationale for grouping together these disorders is 
that their “similarities outweigh their differences” (Dimsdale et al., 2009). As is 
demonstrated in this chapter, a review of the research from the past 30 years indicates the 
clinical characteristics of patients meeting criteria for somatization disorder, undifferentiated 
somatoform disorder, pain disorder, and hypochondriasis (i.e., their presentation of somatic 
symptoms, incorrect illness attributions, health anxiety, and abnormal illness behavior) are 
almost identical. In reviewing the epidemiology of somatization disorder and 
hypochondriasis, Creed and Barksy state there is not sufficient evidence to distinguish 
between even these two disorders (Creed & Barsky, 2004). The similarity in treatment response 
also has been used to argue for a combining of these categories (Dimsdale et al., 2009). In 
addition, the DSM-5 Somatic Symptom Disorders Work Group cite the research showing 
physicians see the somatoform disorders as overlapping disorders (Dimsdale, Sharma, & 
Sharpe, 2011) as a rationale for uniting somatization disorder, undifferentiated somatoform 
disorder, pain disorder and hypochondriasis (APA, 2010). 
To receive a diagnosis of complex somatic symptom disorder, patients must complain of at 
least one somatic symptom that is distressing and/or disruptive of their daily lives. Also, 
patients must have at least two of the following emotional/cognitive/behavioral 
disturbances: high levels of health anxiety, disproportionate and persistent concerns about 
the medical seriousness of the symptom(s), and an excessive amount of time and energy 
devoted to the symptoms and health concerns. Finally, the symptoms and related concerns 
must have lasted for at least six months. 
Future research will examine the epidemiology, clinical characteristics, or treatment of 
complex somatic symptom disorder as there is no published research on this diagnostic 
category. 
7.1.2 Simple somatic symptom disorder 
Also new to DSM-5 is the category, simple somatic symptom disorder, which will be used to 
classify somatically-focused presentations that are more transient and presumably less 
severe than those meeting criteria for complex somatic symptom disorder. Specifically, 
simple somatic symptom disorder will be characterized by somatic concerns that have lasted 
for at least one month and that are accompanied by at least one of the 
emotional/cognitive/behavioral disturbances listed in the previous section (e.g., health 
anxiety, concerns about medical seriousness of symptom, or abnormal illness behavior) 
(APA, 2010). Just as for complex somatic symptom disorder, there is no published research 
on the epidemiology, clinical characteristics, or treatment of simple somatic symptom 
disorder. 
7.1.3 Illness anxiety disorder 
Although the DSM-5 Somatic Symptom Disorders Work Group states that most cases of 
DSM-IV hypochondriasis are likely to meet criteria for DSM-5 complex somatic symptom 
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disorder (APA, 2010), an additional category has been created for patients whose health 
anxiety is not associated with any somatic symptoms. This new category, illness anxiety 
disorder, will be characterized by the presentation of no somatic symptoms, or only those 
mild in severity, and a preoccupation with having or acquiring a serious illness. Also 
required for the diagnosis are significant health anxiety about having or acquiring a serious 
illness, excessive behaviors to check one’s illness status or maladaptive behaviors to avoid 
illness concerns, and a persistence of the illness concerns for at least six months (APA, 2010). 
We are not aware of any published research on the epidemiology, clinical characteristics, or 
treatment response of patients presenting with this “pure” form illness anxiety. 
7.1.4 Functional neurological disorder 
The proposal for conversion disorder in DSM-5 is to retain the category with slight changes. 
First, the category will be renamed functional neurological disorder. Second, DSM-IV’s 
requirement that the symptom(s) not be intentionally produced or feigned by the patient 
will be eliminated, given the difficulty clinicians are likely to have making such a 
determination. Also no longer required will be the judgment that psychological factors are 
associated with the symptom(s). Functional neurological disorder is the one somatic 
symptom disorder category that will retain the dualistic diagnostic criterion of the 
symptom(s) being medically unexplained. The DSM-5 Somatic Symptom Disorders Work 
Group cites the recent evidence that neurologists can reliably make the distinction between 
organic and functional neurological symptoms (Stone, 2009). 
7.1.5 Other disorders 
The current plan for BDD is to move it from the somatic symptom disorders section to the 
obsessive-compulsive and related disorders section (APA, 2010). The research showing the 
similarities between the symptomatology and treatment response of BDD and obsessive-
compulsive disorder (Castle, Rossell, & Kyrios, 2006) has been used to justify this change. 
The diagnostic criteria for DSM-5 BDD now specify that patients need to have performed 
repetitive behaviors or mental acts in response to appearance concerns at some point during 
the disorder (APA, 2010). 
A new addition to the somatic symptom disorders group will psychological factors affecting 
medical condition that has resided in the “other conditions” category. This regrouping has 
been suggested because this condition, whose diagnostic criteria appear to have minimal 
change from that in DSM-IV, is characterized by the presentation of somatic symptoms 
and/or distress regarding a medical condition (APA, 2010). Specifically, the DSM-5 criteria 
include (1) the presence of a general medical condition, (2) psychological or behavioral 
factors that affect the medical condition. Again, this change is consistent with the attempt to 
avoid distinguishing between medically explained and unexplained physical symptoms. 
7.2 Future research on cognitive behavioral treatment of somatoform disorders 
One hurdle in administering CBT to somatically-focused patients is that most of these 
patients seek treatment in primary care, not in psychiatric clinics. When patients with 
somatoform symptoms are referred to mental health treatment, it is estimated that 50 to 90% 
of these patients fail to complete the referral (Escobar, Waitzkin, et al., 1998; Reiger et al., 
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1988). Impediments to successful psychiatric referral of patients presenting with 
somatization occur at both the professional institutional level (e.g., lack of collaboration 
between primary care and mental health practitioners, lack of mental health training for 
primary care physicians, inadequate mental health insurance) and level of the individual 
patient (e.g., concerns about the stigma of having a psychiatric disorder, resistance to 
psychiatric diagnosis, health beliefs that lead to somatic presentations, pessimism, and 
fatigue) (Freidl et al., 2007; Pincus, 2003). This literature suggests that the effectiveness of 
CBT for the somatoform disorders would be enhanced if treatment were conducted in 
primary care settings where the overwhelming majority of these patients are seen. Also, as 
suggested by the research on somatization, an integration of mental health providers into 
primary care and collaboration with primary care physicians and staff would seem 
imperative in that it could increase the acceptability and availability of CBT. Additional 
research is required to substantiate these recommendations.  
As we move forward to refine the treatment of patients with somatic symptom disorders, 
one direction for future research is to improve treatment outcome. As a whole, cognitive 
and behavioral treatments have been shown to reduce physical discomfort, health anxiety, 
and functional limitations in these patients. Although even the most severely and 
chronically disturbed somatization and hypochondriacal patients have benefited from 
treatment, a majority of the treated patients continued to suffer with significant 
symptomatology after treatment ended (see Woolfolk & Allen, 2007, for review). Long-
term benefits have been demonstrated in only a few trials. Also, there is little data on the 
impact of treatment on health care utilization, especially when the cost of a psychosocial 
intervention is factored in to the equation. The investigation of longer-term treatments has 
been recommended for patients who are severely or chronically disturbed (Woolfolk & 
Allen, 2007). Some researchers have argued for studying a stepped-care approach in 
which all patients would receive low-intensity targeted primary care management. 
Response to this initial phase of treatment would guide the level of intensity of additional 
treatment and possible referral to mental health specialists (Arnold et al., 2009; Fink & 
Rosendal, 2008). 
We have very little data on the mechanisms by which cognitive behavioral treatments have 
their impact upon somatoform disorders. There are multiple reasons for this. First, the 
mediators and moderators style of research has not been extensively applied to research on 
somatoform disorders. Second, the treatments studied have not been disassembled into 
discrete components and those constituents systematically assessed. Evidence that might 
shed some light on this issue, that pertaining to differential efficacy of treatment, is also 
scant. This absence of evidence, to some extent, is the result of much overlap among 
treatments. When reading the somatoform treatment literature, careful attention must be 
paid to methods sections, as the labeling of treatments can often be somewhat misleading. 
Future research could be directed towards examining what components of CBT are most 
beneficial to somatic symptoms vs. cognitive dysfunctions vs. health anxiety vs. abnormal 
illness behavior.  
8. Conclusion  
Although the literature on the specific somatoform disorders is relatively small, a few 
global conclusions can be posited. CBT for somatization, hypochondriasis, and BDD has 
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been empirically supported. Specific elements of the cognitive behavioral interventions 
examined for the different somatoform disorders are outlined in Table 2. There is 
inadequate data on the treatment of conversion disorder or of pain disorder to make any 
conclusion.  
Diagnosis Elements of CBT 
Somatization disorder/Undifferentiated 
somatoform disorder 
Identifying and restructuring cognitions 
Altering illness behavior/Behavioral 
activation 
Relaxation training 
Involvement of spouse or family member 
Elicitation and expression of emotion 
Hypochondriasis Identifying and restructuring cognitions 
Exposure plus response prevention 
Conversion Disorder Identifying and restructuring cognitions 
Altering illness behavior/behavioral 
activation 
Relaxation training 
Body dysmorphic disorder Identifying and restructuring cognitions 
Exposure plus response prevention 
Pain disorder -- 
Table 2. Specific elements of CBT examined with specific somatoform disorders 
An evaluation of the empirical research on CBT for somatoform disorders suggests that in 
some respects it mirrors the literature on evaluating the efficacy of psychotherapy literature 
with various mental disorders. CBT has been shown to be superior to various control 
conditions, especially waiting lists or standard medical treatment. Effect sizes are 
respectable, relative to other medical or quasi-medical interventions.  
There are three clear directions recommended for enhancing the efficacy and effectiveness of 
CBT for somatoform disorders. The first is to treat patients in the treatment setting where 
they seek treatment, i.e., primary care settings. Second is to integrate mental health care 
providers into the primary care treatment setting. And, the third is to increase the length of 
CBT for patients who are willing to engage in CBT. Two meta-analyses, one on psychosocial 
treatments of somatization (Kleinstäuber, Witthöft, & Hiller, 2011), the other on 
psychosocial treatment of hypochondriasis (Thomson & Page, 2007), found a positive 
association between length of treatment and outcome, suggesting longer term treatments 
may be more potent. 
The treatment of somatoform disorders via CBT is very much in its infancy. The 
methodological quality of the early research has been uneven. Nevertheless, there is 
sufficient evidence to believe that cognitive behavioral interventions have therapeutic value 
for a number of the disorders. For somatization, hypochondriasis, and BDD, CBT is the 
treatment of choice given that no other intervention has demonstrated efficacy.  
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